Next Article in Journal
Assessment of the Impact of Deformable Registration of Diagnostic MRI to Planning CT on GTV Delineation for Radiotherapy for Oropharyngeal Carcinoma in Routine Clinical Practice
Previous Article in Journal
Factors Underlying Racial Disparities in Sepsis Management
Previous Article in Special Issue
The Oral Healthcare System in Japan
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessReview

Sclerostin Modulation Holds Promise for Dental Indications

1
Division of Craniofacial Anomalies, Department of Orofacial Sciences, University of California San Francisco, San Francisco, CA 94143, USA
2
Department of Orthodontics, Faculty of Dentistry, Alexandria University, Alexandria 21526, Egypt
3
Department of Orthodontics, Faculty of Oral and Dental Medicine, South Valley University, Qena 83523, Egypt
4
Department of Orthodontics, School of Dental Medicine, Case Western Reserve University, Cleveland, OH 44106-4905, USA
5
Department of Periodontics, School of Dental Medicine, Case Western Reserve University, Cleveland, OH 44106-4905, USA
*
Author to whom correspondence should be addressed.
Healthcare 2018, 6(4), 134; https://doi.org/10.3390/healthcare6040134
Received: 4 October 2018 / Revised: 13 November 2018 / Accepted: 20 November 2018 / Published: 23 November 2018
(This article belongs to the Special Issue Dental Care)
  |  
PDF [930 KB, uploaded 23 November 2018]
  |  

Abstract

Sclerostin modulation is a novel therapeutic bone regulation strategy. The anti-sclerostin drugs, proposed in medicine for skeletal bone loss may be developed for jaw bone indications in dentistry. Alveolar bone responsible for housing dentition share common bone remodeling mechanisms with skeletal bone. Manipulating alveolar bone turnover can be used as a strategy to treat diseases such as periodontitis, where large bone defects from disease are a surgical treatment challenge and to control tooth position in orthodontic treatment, where moving teeth through bone in the treatment goal. Developing such therapeutics for dentistry is a future line for research and therapy. Furthermore, it underscores the interprofessional relationship that is the future of healthcare. View Full-Text
Keywords: sclerostin; anti-sclerostin; bone remodeling; alveolar bone; orthodontic; tooth movement; periodontitis; bone loss sclerostin; anti-sclerostin; bone remodeling; alveolar bone; orthodontic; tooth movement; periodontitis; bone loss
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Hassan, M.G.; Zaher, A.R.; Palomo, J.M.; Palomo, L. Sclerostin Modulation Holds Promise for Dental Indications. Healthcare 2018, 6, 134.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Healthcare EISSN 2227-9032 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top